卡非佐米(Carfilzomib) - 药物靶点：Proteasome_在研适应症：多发性骨髓瘤，难治性多发性骨髓瘤，复发性多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Carfilzomib (JAN/USAN/INN)

+ [4]

靶点

Proteasome

作用方式

抑制剂

作用机制

蛋白酶体抑制剂

治疗领域

肿瘤免疫系统疾病心血管疾病+ [2]

在研适应症

多发性骨髓瘤难治性多发性骨髓瘤复发性多发性骨髓瘤+ [10]

非在研适应症

成人急性淋巴细胞白血病淋巴母细胞淋巴瘤成人T细胞白血病/淋巴瘤+ [32]

原研机构

Onyx Pharmaceuticals, Inc.

在研机构

BeiGene Ltd.

SanofiDSM Pharmaceutical Products, Inc.

+ [12]

非在研机构

Onyx Therapeutics, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2012-07-20),

多发性骨髓瘤

最高研发阶段(中国)批准上市

特殊审评附条件批准 (中国)、特殊审批 (中国)、孤儿药 (日本)、快速通道 (美国)、加速批准 (美国)

登录后查看时间轴

结构/序列

分子式C40H57N5O7

InChIKeyBLMPQMFVWMYDKT-NZTKNTHTSA-N

CAS号868540-17-4

Sequence Code 16182110

关联

251

项与卡非佐米相关的临床试验

NCT06627751

/ Not yet recruiting临床2期IIT

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)

This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease [EMD]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed/refractory multiple myeloma (RRMM) with EMD.

开始日期2025-04-01

申办/合作机构

Roswell Park Comprehensive Cancer Center

NCT06622005

/ Not yet recruiting临床1期IIT

Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

This phase I trial tests the safety and side effects of SX-682 in combination with standard of care treatment carfilzomib, daratumumab-hyaluronidase, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). SX-682 works by blocking certain sites on cells that suppress the ability of the immune system to destroy tumor cells. Blocking those specific sites allows other cells of the immune system to become "free" to kill tumor cells. Carfilzomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and tumor cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill tumor cells, while hyaluronidase helps to deliver daratumumab to CD38-expressing tumor cells through a subcutaneous injection. Dexamethasone is in a class of medications called corticosteroids. It is known to kill myeloma cells and is also used to reduce inflammation and lower the body's immune response to monoclonal antibodies like dratumumab and help lessen its side effects. Giving SX-682 in combination with carfilzomib, daratumumab-hyaluronidase and dexamethasone may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma

开始日期2025-04-01

申办/合作机构

Roswell Park Comprehensive Cancer Center

NCT06356571

/ Recruiting临床2期

A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.

开始日期2025-03-31

申办/合作机构

Sanofi

100 项与卡非佐米相关的临床结果

登录后查看更多信息

100 项与卡非佐米相关的转化医学

登录后查看更多信息

100 项与卡非佐米相关的专利（医药）

登录后查看更多信息

2,519

项与卡非佐米相关的文献（医药）

2025-04-01·Clinical Microbiology and Infection

Phenotypic and genotypic correlates of the sodium bicarbonate-responsive phenotype among methicillin-resistant Staphylococcus aureus isolates from skin and soft-tissue infections

Article

作者: Harrison, Ewan M ; Bayer, Arnold S ; Xiong, Yan Q ; Ersoy, Selvi C ; Kreiswirth, Barry ; Proctor, Richard A ; Patel, Robin ; Blane, Beth ; Mediavilla, Jose ; Peacock, Sharon J ; Miller, Loren G ; Chen, Liang ; Flores, Evelyn A ; Chambers, Henry F ; Madrigal, Sabrina L

OBJECTIVESThe objective of this study is to assess the frequency of the novel sodium bicarbonate (NaHCO₃)-responsive phenotype, wherein clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates are rendered susceptible to standard-of-care β-lactams in the presence of NaHCO₃, in a collection of 103 clinical U.S. MRSA skin and soft-tissue infection (SSTI) isolates and 22 clinical European SSTI isolates. This study determined the correlation between specific phenotypic and genotypic metrics and the NaHCO₃-responsive phenotype among U.S. SSTI isolates.METHODSAntimicrobial susceptibility testing was performed to determine susceptibility phenotypes. Targeted and whole-genome sequencing with a genome-wide sequence analysis were conducted to identify specific and novel genotypes of interest that may be associated with the NaHCO₃-responsive phenotype. Gene expression analysis and targeted gene deletion were performed to assess the role of a specific novel genetic locus in the NaHCO₃-responsive phenotype.RESULTSThe NaHCO₃-responsive phenotype was identified in 78/103 U.S. isolates and 4/22 UK isolates to cefazolin (CFZ), and in 17/103 U.S. isolates and 1/22 UK isolates to oxacillin. In U.S. isolates, a significant association was identified between NaHCO₃-responsiveness to CFZ and: (a) susceptibility to amoxicillin-clavulanate; (b) a specific mecA genotype; (c) clonal complex type 8; and (d) spa type t008. Genome-wide sequence analysis identified single nucleotide polymorphisms (SNPs) in an AraC family regulator (SAUSA300_RS00540) to be exclusively found in NaHCO₃-non-responsive SSTI strains. In vitro HCO₃ exposures of NaHCO₃-responsive strains, but not -non-responsive strains, caused >2-fold upregulated expression of this gene. Deletion of this gene rendered NaHCO₃-responsive strain MRSA 11/11 no longer NaHCO₃-responsive to CFZ; we have termed this gene the staphylococcal AraC bicarbonate-response regulator.DISCUSSIONNaHCO₃-responsiveness is highly associated with clonal complex type 8/spa type t008, a commonly circulating genetic background in North America. The AraC bicarbonate-response regulator, staphylococcal AraC bicarbonate-response regulator, appears to be associated with the mechanism of NaHCO₃-responsiveness, but more work is needed to verify.

2025-03-01·Allergy and Asthma Proceedings

Rapid drug desensitization in seven patients with delayed hypersensitivity reactions to biologics and targeted therapies: Reason, successes, and failures

Article

作者: Evcen, Recep ; Colkesen, Fatih ; Gerek, Mehmet Emin ; Arslan, Sevket ; Akkus, Fatma Arzu ; Onalan, Tugba

Backround: Rapid drug desensitization (RDD) is commonly used for immediate drug hypersensitivity reactions (DHR) across various drugs. In delayed DHRs, the conventional approach is slow desensitization; however, limitations may arise due to drug-specific or disease-related factors. With the increasing role of targeted molecular drugs in delayed DHRs, data on the efficacy of RDD in these contexts remain scarce. Objective: This case series aims to explore the rationale and outcomes of RDD in managing delayed DHRs associated with targeted therapies. Methods: We analyzed data from patients referred to a tertiary university hospital's drug allergy outpatient clinic between January 2021 and April 2024. The subjects experienced delayed DHRs during treatment with targeted drugs and, subsequently, underwent RDD. Results: The drugs administered via RDD included bevacizumab, rituximab, daratumumab, lenalidomide, bortezomib, and carfilzomib. The index reactions included maculopapular eruptions (MPE), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Delayed breakthrough reactions were observed in four of seven patients. RDD with bortezomib was unsuccessful in all three patients, and delayed reactions were observed in all patients with severe cutaneous adverse reactions (AGEP and DRESS). Conclusion: Suggesting significant success of RDD for delayed DHRs induced by targeted therapies may be overly optimistic. Nevertheless, four of seven patients, including one with AGEP, were able to continue their treatment. Managing patients with advanced diseases and delayed DHR poses notable challenges. The risk to patient survival from withholding life-saving medication must be weighed against the risks of desensitization. The low sensitivity of skin tests and the critical waiting period complicate decision-making. Given the unique contribution of targeted agents in the treatment of severe, life-threatening diseases, further research on desensitization is warranted.

2025-03-01·Transplantation and Cellular Therapy

Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation

Article

作者: Shpall, Elizabeth J ; Pal, Babar ; Lin, Paul ; Wang, Zhongya ; Champlin, Richard E ; Tang, Guilin ; Ye, Christine ; Qazilbash, Muzaffar H ; Bashir, Qaiser ; Srour, Samer ; Ramdial, Jeremy ; Becnel, Melody R ; Kebriaei, Partow ; Tanner, Mark R ; Pasvolsky, Oren ; Syed, Naureen ; Nieto, Yago ; Marcoux, Curtis ; Thomas, Sheeba K ; Milton, Denái R ; Saini, Neeraj ; Orlowski, Robert Z ; Aljawai, Yosra ; Patel, Krina K ; Lee, Hans C

Patients with multiple myeloma (MM) without high-risk cytogenetic abnormalities are classified as having standard-risk MM (SRMM), and data focusing on their outcomes after autologous hematopoietic stem cell transplantation (autoHCT) are limited. We sought to evaluate survival outcomes for patients with SRMM receiving autoHCT, and to elucidate factors that impact these outcomes. This was a single-center retrospective analysis that included consecutive MM patients who received upfront autoHCT between 2013 and 2021, had available cytogenetic information and had no high-risk chromosomal abnormalities on fluorescence in situ hybridization, defined as t(4;14), t(14;16), del(17p) or 1q21 gain or amplification. A total of 1000 SRMM patients were included, with a median age of 61 years (range 25 to 83), and 61% were male (n = 612). The most common induction regimens were bortezomib/lenalidomide/dexamethasone (VRD; n = 398, 40%) and carfilzomib/lenalidomide/dexamethasone (KRD; n = 212, 21%), and the majority (87%) received single-agent melphalan as conditioning. After induction and before autoHCT, 16% and 57% achieved ≥complete response (CR) and ≥very good partial response (VGPR), respectively. At day 100 post autoHCT, 37% and 77% achieved ≥CR and ≥VGPR, respectively. Sixty-two percent and 89% of patients achieved ≥ CR and ≥VGPR as best response post-transplant. A minimal residual disease (MRD) negative response pre- and post-transplantation was achieved in 43% (401/936) and 64% (199/311) of patients, respectively. After a median follow-up of 42.1 months, the median progression-free survival (PFS) for the entire cohort was 68.3 months (95% CI 60.1 to 72.1), and the median overall survival (OS) was not reached (95% CI 102.3-not reached). The 5-year PFS and OS rates were 55% and 83%, respectively. In multivariable analysis, achieving MRD-negative CR prior to autoHCT (HR 0.65 [95% CI 0.44 to 0.97], P = .033) or as best response (0.52 [0.34 to 0.78], P = .002), and use of post-transplant maintenance (0.69 [0.52 to 0.93], P = .013) and lenalidomide-based combination maintenance (0.68 [0.48 to 0.96], P = .030) were associated with improved PFS, whereas use of an induction regimen other than KRD was associated with worse PFS (1.50 [1.04 to 2.17], P = .031). For OS, post-transplant maintenance (0.48 [0.32 to 0.70], P < .001) was associated with better survival in multivariable analysis, whereas R-ISS stage III, compared with stage I, (2.34 [1.01 to 5.43], P = .047) was associated with worse OS. Patients with SRMM who received upfront autoHCT had a median PFS of >5.5 years, and median OS was not reached. These results highlight the favorable outcomes with upfront autoHCT for patients with SRMM, serving as a benchmark for future therapeutic approaches in this subgroup of MM patients.

347

项与卡非佐米相关的新闻（医药）

2025-03-14

·抗体密码

强生为什么放弃genmab的CD38抗体

美国时间3月10日，强生宣布放弃对新一代CD38单抗HexaBody-CD38（GEN3014）全球许可开发、生产和商业化的选择权。消息披露之后，该项目的合作方Genmab股价曾一度下跌10%。Genmab在评估了该药物的临床数据和市场环境，最终决定不再继续其临床开发。作为RR/MM领域深刻布局的强生在开发GEN3014之前已经有一款CD38单抗Daratumumab（达雷妥尤单抗）获批上市，那么是什么原因促使强生引进开发GEN3014，那又是为什么又放弃该项目呢。 CD38单抗Daratumumab是强生开发的治疗RR/MM的单克隆抗体，该药物于2015年11月首次被FDA批准用于治疗多发性骨髓瘤患者的四线药物；2016年11月，Daratumumab联合来那度胺和地塞米松，联合硼替佐米和地塞米松两种三联方案获批作为二线治疗方案，用于既往接受过至少一种疗法的多发性骨髓瘤患者；2017年6月，Daratumumab与泊马度胺和地塞米松的三联疗法获FDA批准，用于多发性骨髓瘤患者的三线治疗。2021年12月，FDA）批准daratumumab皮下（SC）制剂——Darzalex Faspro，联合Kyprolis（carfilzomib，卡非佐米）和地塞米松（Kd），用于治疗既往接受过1-3线治疗的复发或难治性多发性骨髓瘤（R/R MM）成人患者。值得一提的是，Daratumumab最初也是来自于Genmab，2012年8月，Genmab公司授予了强生旗下杨森生物科技有限公司（Janssen Biotech, Inc）开发、生产和商业化daratumumab（达雷妥尤单抗）的全球独家许可。而HexaBody-CD38（GEN3014）是Genmab的第二代CD38抗体，该抗体的开发利用了Genmab的CDC增强型平台HexaBody。抗体平台通过对抗体的Fc进行突变，促进抗体形成六聚体，最终达到增强CDC效应并增加抗体的治疗效果。 GEN3014通过HexaBody技术增强抗体的CDC效应，在体外实验中具有较高的抗肿瘤活性，并且优于Daratumumab抗体的效果。除了具有CDC效应外，该抗体同时还可以通过ADCC，ADCP等作用对肿瘤进行杀伤。因此强生期望用活性的更强的GEN3014的对Daratumumab的疗效进一步提升，并于2019年与Genmab达成HexaBody-CD38全球独家研发许可协议。那么又是什么原因导致强生放弃HexaBody-CD38（GEN3014）全球许可开发、生产和商业化的选择权呢？首先我们看一下Genmab披露的临床数据，Genmab的初步临床主要是和Daratumumab进行了头对头比较，临床结果显示，HexaBody-CD38静脉注射组的总体缓解率（ORR）为54.8%，而达雷妥尤单抗皮下注射组为52%；HexaBody-CD38非常好的部分缓解率（VGPR）为28.6%，达雷妥尤单抗为16.7%；完全缓解率（CR）方面。两者分别为7.1%和2.4%。初步结果看两者疗效接近，而HexaBody-CD38在VGPR及CR方面略优于Daratumumab。而在安全性方面，HexaBody-CD38的治疗虽然没有出现新的副作用，但是整体水平要高于Daratumumab，特别是3级及以上TEAE和3级及以上治疗相关TEAE，包括导致剂量延迟的TEAE。因此安全性方面相较于Daratumumab的严重副作用可能是促使强生决定放弃HexaBody-CD38一个主要原因。另外一方面，强生作为RR/MM领域最资深的布局者，其管线中已经有多款靶向RR/MM后线疗法，包括BCMA/CD3双抗《第7款双抗!强生BCMA/CD3双抗获批上市》，GPRC5D/CD3双抗《第11款双抗：强生GPRC5D/CD3双抗获批上市》，《“TCE双抗联合”，强生公布Ⅰ期临床结果！》《不服不行啊！》和来自于传奇生物的BCMA CAR-T疗法，以及在临床中布局的双抗联合，三抗等。因此，即使目前CD38单抗治疗后复发，后续其还有多款药物可以选择，没有必要为了微弱的疗效优势增加安全性风险。如果强生没有CD38药物，想必肯定会继续开发HexaBody-CD38，这也从侧面证明，biotech 公司想要获得MNC的青睐，必须要有过硬的药物。我们已经建立抗体密码读者交流群，有兴趣的可以扫描下方二维码添加微信进群，请主动备注姓名-公司-职位（高校-专业），非诚勿扰！往期精彩回顾抗体密码文章合集双特异抗体平台靶点相关双特异抗体作用机制综述，行业概览抗体筛选技术相关公司技术汇总医药资讯因为你的分享、点赞、在看我足足的精气神儿！声明本公众号所发表文章以宣传知识为目的，因此不构成投资，病人用药等建议。如果文章侵您的权益及时联系小编进行删除！欢迎扫码交流/咨询/合作等素材来源

引进/卖出临床1期抗体药物偶联物

2025-02-26

·PipelineReview

Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma

HEFEI, China I February 25, 2025 I Kangpu Biopharmaceuticals, Ltd. (“Kangpu”) today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) for KPG-818 for the treatment of relapsed/refractory multiple myeloma (RRMM). KPG-818 is a novel oral molecular glue modulator of the E3 ubiquitin ligase complex CRL4-CRBN. It demonstrated high cereblon (CRBN) binding affinity and potent degradation of Aiolos (IKZF3) and Ikaros (IKZF1), two members of the Ikaros family of zinc-finger transcription factors associated with B-cell development. KPG-818 possesses immunomodulatory, anti-angiogenic, and anti-tumor effects. The Phase I clinical trial of KPG-818 in the United States for the treatment of various hematological tumors has been completed. Preliminary results indicate that in RRMM patients who have previously received two immunomodulatory drugs (lenalidomide and pomalidomide), at least one proteasome inhibitor (bortezomib, ixazomib, or carfilzomib), and a CD38 monoclonal antibody (daratumumab or isatuximab), KPG-818 demonstrated good safety, tolerability, pharmacokinetic characteristics, and encouraging therapeutic effects. About Kangpu Biopharmaceuticals Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative therapeutics for the treatment of solid tumors, hematologic malignancies, autoimmune diseases, and inflammatory disorders through novel solutions, including targeted protein degradation. Kangpu has developed a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms, including NeoMIDES ® , gDACs ® , and X-SYNERGY ® . For more information, please visit www.KangpuGroup.com . SOURCE: Kangpu Biopharmaceuticals

临床1期临床申请临床结果免疫疗法临床2期

2025-02-25

·E药经理人

康朴生物医药KPG-818治疗复发或难治多发性骨髓瘤在中国获批临床

中国合肥，2025年2月25日 -- 康朴生物医药技术（合肥）有限公司（“康朴生物医药”）今日宣布，公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意KPG-818胶囊开展用于治疗复发或难治多发性骨髓瘤（RRMM）的临床试验。 KPG-818是康朴生物医药设计开发的具有全球自主知识产权的新一代口服分子胶免疫调节药物，属于1类小分子新药。KPG-818归属E3泛素连接酶复合物CRL4-CRBN调节剂，对靶点CRBN显示出极高的亲和力，可以高效降解锌指转录因子Aiolos（IKZF3）和Ikaros（IKZF1），具有免疫调节、抗血管生成和抗肿瘤作用。 KPG-818在美国开展的治疗多种血液肿瘤的 Ⅰ 期临床试验已经结束，初步结果显示，在既往接受过两个度胺类药物（来那度胺和泊马度胺）、至少1个蛋白酶抑制剂（硼替佐米、伊沙佐米或卡非佐米）及一个CD38单抗（达雷妥尤单抗或艾沙妥昔单抗）的难治或复发末线多发性骨髓瘤患者中展现了良好的安全性、耐受性、药代动力学特征以及令人鼓舞的治疗效果。关于康朴生物医药总部位于安徽省合肥市的康朴生物医药是一家处于临床阶段的创新型生物医药企业。公司拥有一支实力雄厚、具有国际化视野和行业经验的创新药开发资深专家团队及运营团队。立足创新驱动，聚焦自身免疫疾病、癌症、炎症等治疗领域，康朴生物医药以国际领先的分子胶-蛋白质泛素化降解技术NeoMIDES®和gDACs®、X-SYNERGY®等自主专利技术为基础，致力于开发面向全球、具有全球自主知识产权的创新药物。为征服疾病、增进人类生命健康贡献力量。关于公司的更多信息，请浏览www.KangpuGroup.com 一审| 黄佳二审| 李芳晨三审| 李静芝

临床1期蛋白降解靶向嵌合体引进/卖出

100 项与卡非佐米相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08880	卡非佐米	L01XX45	DB08889

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
多发性骨髓瘤	美国	Onyx Pharmaceuticals, Inc.	2012-07-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性多发性骨髓瘤	临床3期	捷克	Amgen, Inc.	2010-09-01
复发性多发性骨髓瘤	临床1期	意大利	Amgen, Inc.	2010-09-01
复发性多发性骨髓瘤	临床1期	澳大利亚	Amgen, Inc.	2010-09-01
复发性多发性骨髓瘤	临床1期	波兰	Amgen, Inc.	2010-09-01
复发性多发性骨髓瘤	临床1期	以色列	Amgen, Inc.	2010-09-01
复发性多发性骨髓瘤	临床1期	塞尔维亚	Amgen, Inc.	2010-09-01
复发性多发性骨髓瘤	临床1期	匈牙利	Amgen, Inc.	2010-09-01
复发性多发性骨髓瘤	临床1期	比利时	Amgen, Inc.	2010-09-01
复发性多发性骨髓瘤	临床1期	英国	Amgen, Inc.	2010-09-01
多发性骨髓瘤	临床1期	塞尔维亚	Amgen, Inc.	2010-07-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02101944 (Pubmed) 人工标引	临床1期	多发性骨髓瘤	13	Pelareorep + carfilzomib	(製壓壓糧製網廠積製窪) = 簾範鹹網夢襯觸襯觸選獵衊觸遞願築齋觸構窪 (獵選鏇鬱醖鑰蓋範憲構 )	积极	2025-01-20
NCT02332850 (ASH2024) 人工标引	临床2期	多发性骨髓瘤	50	IsatuximabCarfilzomibDexamethasone	(鑰簾艱積網願鬱鬱鏇憲) = 鏇鑰餘簾範鹹網壓選膚鏇醖願窪糧廠願鬱齋積 (衊繭鏇膚齋願構壓範淵 ) 更多	积极	2024-12-07
EXTH-54 (SNO2024)	N/A	脑膜瘤	20	Carfilzomib	醖艱鹹簾壓構積簾廠範(蓋襯製選選網願鏇齋獵) = 齋鏇範遞選蓋鹽夢糧糧糧築蓋餘範艱艱網遞鬱 (繭蓋鑰積淵鏇簾艱鹹簾 )	积极	2024-11-11
NCT02002598 (CTgov)	临床1/2期	多发性骨髓瘤	23	Bendamustine+Carfilzomib+Dexamethasone	餘廠淵艱鏇觸願願壓艱(願選窪襯遞衊觸積鏇襯) = 衊齋範膚繭糧願齋醖簾餘簾顧糧選遞積醖艱醖 (繭壓積夢遞積繭鹽鏇襯, 餘衊築壓衊夢顧鏇網壓 ~ 餘築襯襯糧廠餘構鹹齋) 更多	-	2024-09-19
MM-174 (SOHO2024)	N/A	多发性骨髓瘤	25	Carfilzomib 70 mg/m2 + Dexamethasone 40 mg	夢積衊獵鹽觸夢範鹹積(觸襯鏇鹽衊顧顧獵獵範) = 92% 積鹽襯遞窪觸壓顧鹹網 (構遞餘衊糧遞衊鏇襯繭 ) 更多	积极	2024-09-04
NCT03859427 (A.R.R.O.W.2, Pubmed) 人工标引	临床3期	多发性骨髓瘤	454	Once-weekly carfilzomib 56 mg/m2 plus Rd (KRd56)	(膚醖構繭築範鏇繭壓膚) = 窪壓選憲網鏇選餘築夢製鹹範鑰觸衊鹹壓簾網 (壓觸糧蓋鑰衊構製鑰蓋, 76.9‒87.2) 未达到更多	不佳	2024-07-18
NCT03859427 (A.R.R.O.W.2, Pubmed) 人工标引	临床3期	多发性骨髓瘤	454	Twice-weekly carfilzomib 27 mg/m2 plus lenalidomide and dexamethasone (KRd27)	(膚醖構繭築範鏇繭壓膚) = 餘淵壓壓鬱餘衊選憲壓製鹹範鑰觸衊鹹壓簾網 (壓觸糧蓋鑰衊構製鑰蓋, 81.1‒90.5) 未达到更多	不佳	2024-07-18
NCT04113018 (MRD-driven phase 2 study \| LCI-HEM-MYE-KRDD-001, CTgov)	临床2期	多发性骨髓瘤	39	lenalidomide+Carfilzomib+Daratumumab+dexamethasone (KRd)	鹽鏇淵糧顧築壓鏇衊鏇(膚選願艱餘餘願遞繭構) = 憲壓網範夢獵衊製餘鹽鹽艱鏇鬱窪夢鏇鏇艱鑰 (遞鬱憲鹽夢鹹夢願獵鑰, 繭夢選獵顧鏇糧製鏇獵 ~ 遞鏇鹹網簾願鏇簾製繭) 更多	-	2024-07-16
NCT02073097 (CTgov)	临床1/2期	弥漫性大B细胞淋巴瘤	48	Pegfilgrastim+Acyclovir+Carfilzomib+cyclophosphamide+Prednisone+doxorubicin hydrochloride+Rituximab+Vincristine sulfate	構積獵衊鏇築鬱構窪齋(艱繭壓範壓顧鹹襯鬱積) = 鏇遞繭膚觸廠壓餘鑰壓艱觸製淵鏇衊憲夢鏇構 (製膚鏇積糧選遞願窪積, 淵範餘壓襯醖顧廠築糧 ~ 齋夢衊觸範鹹網鹽艱選) 更多	-	2024-05-29
NCT01959698 (CORAL, ASCO2024)	临床1/2期	复发性弥漫性大B细胞淋巴瘤 Bcl-2 family members	-	Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE)	(範襯壓糧築窪鬱顧襯鏇) = 選鏇窪鑰餘築衊網構糧餘艱壓廠壓鏇網膚艱範 (憲廠齋遞齋壓廠醖廠衊 ) 更多	积极	2024-05-24
NCT01959698 (CORAL, ASCO2024)	临床1/2期	复发性弥漫性大B细胞淋巴瘤 Bcl-2 family members	-	RICE	(範襯壓糧築窪鬱顧襯鏇) = 鬱顧範築積醖窪範廠齋餘艱壓廠壓鏇網膚艱範 (憲廠齋遞齋壓廠醖廠衊 ) 更多	积极	2024-05-24
NCT03606577 (Pubmed \| Blood) 人工标引	临床2期	多发性骨髓瘤巩固 \| 一线 \| 诱导	50	Daratumumab-cacarfilzomibenalenalidomideamedexamethasoned)	積繭選糧膚廠醖醖築顧(淵壓夢範鏇鹹鹽網鹹積) = the study met the primary end point with 36 patients completing second transplant 網淵積鏇衊顧製遞鏇襯 (鏇願廠範壓鹹觸網廠簾 ) 达到更多	积极	2024-05-16